Participants - All

BD Director at Novalix, a drug discovery CRO supporting biotech, pharma and academia. We offer integrated medicinal chemistry, screening, structural biology, biophysics, DMPK and in vivo pharmacology, from early discovery to preclinical development.

Final-year PhD (CIMA, UNAV) in small-molecule drug discovery & novel modalities: PROTACs, DEL hits, SAR, novel E3 ligases. Hybrid computational + chemical biology profile. Seeking industry roles in computational/AI-driven/hybrid drug discovery from 2027.

At Synex Biosystems, we help labs use their existing data to understand biological variability and predict experimental outcomes. Looking to connect with drug discovery and cell therapy teams to explore working together.

I am bridging the gap between computational chemistry and medicinal chemistry.

Experienced organic & medicinal chemist with 20+ years’ expertise in drug discovery, from custom synthesis to preclinical development. Skilled in med-chem, strategic planning and multidisciplinary team leadership. PhD in Organic Chemistry.

I work for the development of next-generation medicines based on photopharmacology. At MCS we design drugs that can be switched on and off using light offering unmatched pharmacological precision. I am keen to exchange ideas and explore opportunities!

We are a group specialized on chemical probe development, classical medicinal chemistry and macrocyclic peptide discovery for hard-to-drug targets. Interested on exploring joint projects on drug discovery and diagnostics.

Helping pharma, biotech and diagnostics teams move R&D projects forward with tailored NGS and multi-omics solutions. I’d love to learn about your projects and explore how Novogene could support them.

SmartBio es el primer lab bioanalítico en Madrid. Colaboramos con empresas farma, biotec y centros de i+d para acelerar el desarrollo de nuevos medicamentos

I hold a degree in Biotechnology, over two years of experience in biochemistry and molecular biology laboratories, and a Master's degree in experimental neuroscience.

Neuroscientist and EBRI Group Leader specializing in NGF biology, microglia, neuroinflammation and electrophysiology. I am helping advance Super NGF, a clinical-grade TrkA-biased therapeutic, toward clinical development for ocular and CNS disorders.

Biotech CEO

I’m a physicist and Innovation Project Manager at ingenyus, specializing in scientific, medical, and environmental communication. I connect science, strategy, and knowledge transfer to make R&D&I more accessible, increase its impact, and foster synergies.

Advancing small molecule research to address diseases with significant unmet medical needs. Dedicated to developing innovative therapies aimed at improving patient outcomes in areas where current treatments fall short.

Experienced businesswoman specialized in the pharma, agro, and chemical industries, with a passion for bridging Science and Business. I focus on high-quality CROs that deliver scientific excellence and reliable results.

PhD student working on Alzheimer's disease, with special focus on proteomics, and drug repositioning

Experts in quantitative molecular imaging. We validate biologic drug candidates in vivo during preclinical development, with fewer animals and greater precision, reducing uncertainty in lead selection.

Product Manager at Promega Ibérica driving market expansion and sales enablement. Dedicated to translating deep customer insights into competitive advantages and building high-impact, strategic go-to-market strategies in life sciences.

Helping researchers and biotech innovators find the right Life Sciences technologies. Our portfolio covers Animal & Cell Imaging, Bioprinting, Cell Processing and Biomolecular Interaction Analysis for drug discovery and advanced research

Stefano has 15+ years’ expertise in preclinical drug discovery, molecular biology and in vivo pharmacology. He has led R&D programs, secured international grants, built high-performing teams, and holds a PhD in Neuroscience.